Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2003 2
2004 1
2005 2
2006 1
2007 7
2008 3
2009 4
2010 3
2011 3
2012 10
2013 4
2014 2
2015 2
2016 2
2017 4
2018 5
2019 4
2020 1
2021 2
2022 1
2023 6
2024 12
2025 4
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Stein Gold L, et al. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21. Am J Clin Dermatol. 2022. PMID: 34674160 Free PMC article. Clinical Trial.
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicente …
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl …
Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment.
Draelos ZD, Baalbaki N, Colon G, Dreno B. Draelos ZD, et al. J Drugs Dermatol. 2023 Jun 1;22(6):554-558. doi: 10.36849/JDD.7142. J Drugs Dermatol. 2023. PMID: 37276158 Clinical Trial.
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicular keratinization and BPO to decrease the C. acnes population. .. …
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl …
CABTREO(TM) (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel.
Gupta AK, Mann A, Vincent K, Abramovits W. Gupta AK, et al. Skinmed. 2024 Oct 22;22(5):375-378. eCollection 2024. Skinmed. 2024. PMID: 39433524 Clinical Trial.
Cabtreo(TM) (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) or IDP-126 topical gel was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of moderate to severe acne vulgaris in patients aged 12 yea …
Cabtreo(TM) (1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide) or IDP-126 topical gel was approve …
Adapalene/Benzoyl Peroxide Gel 0.3%/2.5%: A Safe and Effective Acne Therapy in All Skin Phototypes.
Alexis AF, Cook-Bolden FE, York JP. Alexis AF, et al. J Drugs Dermatol. 2017 Jun 1;16(6):574-581. J Drugs Dermatol. 2017. PMID: 28686775 Clinical Trial.
This analysis investigated possible differences in the efficacy and safety of the fixed dose combination of 0.3% adapalene with 2.5% benzoyl peroxide (A/BPO gel 0.3%/2.5%) in subjects with Fitzpatrick Skin Types (FST) I-VI....
This analysis investigated possible differences in the efficacy and safety of the fixed dose combination of 0.3% adapalene with 2.5% …
Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents.
Eichenfield LF, Hebert AA, Harper JC, Baldwin H, Bhatia N, Gold LS, Kircik LH, Graber E, Tanghetti EA, Alexis AF, Del Rosso JQ. Eichenfield LF, et al. J Drugs Dermatol. 2024 Dec 1;23(12):1049-1057. doi: 10.36849/jdd.8643. J Drugs Dermatol. 2024. PMID: 39630680 Clinical Trial.
BACKGROUND: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose triple-combination approved for acne (indicated in patients 12 years and older). ...
BACKGROUND: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose t …
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis.
Lain ET, Bhatia N, Kircik L, Gold LS, Harper JC, Bunick CG, Guenin E, Baldwin H, Feldman SR, Rosso JQD. Lain ET, et al. J Drugs Dermatol. 2024 Oct 1;23(10):873-881. doi: 10.36849/JDD.2024.8484. J Drugs Dermatol. 2024. PMID: 39361705 Clinical Trial.
BACKGROUND: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the only fixed-dose triple-combination treatment approved for acne. ...
BACKGROUND: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the only fixed-dose triple-co …
Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris.
Aschoff R, Möller S, Haase R, Kuske M. Aschoff R, et al. J Drugs Dermatol. 2021 Mar 1;20(3):295-301. doi: 10.36849/JDD.2021.5641. J Drugs Dermatol. 2021. PMID: 33683070 Clinical Trial.
This evaluator-blinded pilot study compared the efficacy and tolerability of two marketed topical combination acne gels, clindamycin 1%-tretinoin 0.025% (CT) and benzoyl peroxide 2.5%-adapalene 0.1% (BA) in 20 patients with mild to moderate acne vulgaris. ...
This evaluator-blinded pilot study compared the efficacy and tolerability of two marketed topical combination acne gels, clindamycin 1%-tret …
Anti-Inflammatory Dose Doxycycline Plus Adapalene 0.3% and Benzoyl Peroxide 2.5% Gel for Severe Acne.
Kircik LH. Kircik LH. J Drugs Dermatol. 2019 Sep 1;18(9):924-927. J Drugs Dermatol. 2019. PMID: 31524349 Clinical Trial.
Anti-inflammatory dose doxycycline (40mg: 30mg immediate release and 10mg delayed release beads) is approved for the treatment of rosacea but with demonstrated efficacy for acne. Fixed combination adapalene 0.3% and benzoyl peroxide 2.5% gel is a once-daily f …
Anti-inflammatory dose doxycycline (40mg: 30mg immediate release and 10mg delayed release beads) is approved for the treatment of rosacea bu …
Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris.
Korkut C, Piskin S. Korkut C, et al. J Dermatol. 2005 Mar;32(3):169-73. doi: 10.1111/j.1346-8138.2005.tb00739.x. J Dermatol. 2005. PMID: 15863861 Clinical Trial.
Benzoyl peroxide and adapalene are among the most effective topical agents used in the treatment of acne. ...The groups were randomly assigned to 0.1% adapalene gel, 5% benzoyl peroxide lotion, or combination of 0.1% adapalene gel …
Benzoyl peroxide and adapalene are among the most effective topical agents used in the treatment of acne. ...The groups …
Investigation of the effect of adapalene 0.3%/benzoyl peroxide 2.5% gel in Korean patients with acne: a randomized, double-blind clinical trial, with a histopathological and immunohistochemical study.
Lee JH, Kim DH, Yoon JY, Kim TM, Kim SR, Suh DH. Lee JH, et al. Ital J Dermatol Venerol. 2024 Aug;159(4):444-452. doi: 10.23736/S2784-8671.24.07800-9. Ital J Dermatol Venerol. 2024. PMID: 39069843 Clinical Trial.
BACKGROUND: Acne vulgaris poses significant physical and psychological challenges worldwide. Data of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) for acne treatment in Asian patients is limited. ...
BACKGROUND: Acne vulgaris poses significant physical and psychological challenges worldwide. Data of adapalene 0.3%/benzoyl …
80 results